Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies

被引:18
作者
Dichtelmueller, Herbert O.
Biesert, Lothar
Fabbrizzi, Fabrizio
Falbo, Anna
Flechsig, Eckhard
Groener, Albrecht
von Hoegen, Ilka [1 ]
Kempf, Christoph
Kreil, Thomas R.
Lee, Douglas C.
Poelsler, Gerhard
Roth, Nathan J.
机构
[1] PPTA, B-1200 Brussels, Belgium
关键词
LIPID-ENVELOPED VIRUSES; DERIVATIVES; HEPATITIS; REMOVAL; SCALE; SERUM;
D O I
10.1111/j.1537-2995.2010.03003.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUND: Virus removal by partitioning into different fractions during cold ethanol fractionation has been described by several authors, demonstrating that cold ethanol fractionation can provide significant contribution to virus removal, even in those cases where virus removal is limited and must be supported by additional measures for virus inactivation during further processing. STUDY DESIGN AND METHODS: Plasma Protein Therapeutics Association (PPTA) member companies collected and evaluated 615 studies on virus removal by the steps of the cold ethanol fractionation process. The studies describe the precipitation and separation of Fraction (F) III or FI/III in the immunoglobulin fractionation process and precipitation and separation of FII/III, FI/II/III, and FIV/IV in the albumin fractionation process. RESULTS: The data indicate a significant contribution of cold ethanol fractionation to the overall clearance of a broad spectrum of viruses, at varied process variables such as pH, temperature, and alcohol concentration and demonstrate the robustness of virus removal by the cold ethanol fractionation process. CONCLUSIONS: The data presented here support the importance of the partitioning steps for virus safety for immunoglobulins and albumin. However, virus removal by cold ethanol fractionation alone cannot provide viral safety of human albumin and immunoglobulins and therefore must be completed by other virus inactivation and removal procedures.
引用
收藏
页码:1412 / 1430
页数:19
相关论文
共 26 条
[1]
Biesert L, 1996, CLIN EXP RHEUMATOL, V14, pS47
[2]
Virus safety of intravenous immunloglobulin -: Future challenges [J].
Boschetti, N ;
Stucki, M ;
Späth, PJ ;
Kempf, C .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2005, 29 (03) :333-344
[3]
PREPARATION AND PROPERTIES OF SERUM AND PLASMA PROTEINS .4. A SYSTEM FOR THE SEPARATION INTO FRACTIONS OF THE PROTEIN AND LIPOPROTEIN COMPONENTS OF BIOLOGICAL TISSUES AND FLUIDS [J].
COHN, EJ ;
STRONG, LE ;
HUGHES, WL ;
MULFORD, DJ ;
ASHWORTH, JN ;
MELIN, M ;
TAYLOR, HL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1946, 68 (03) :459-475
[4]
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies [J].
Dichtelmueller, Herbert O. ;
Biesert, Lothar ;
Fabbrizzi, Fabrizio ;
Gajardo, Rodrigo ;
Groener, Albrecht ;
von Hoegen, Ilka ;
Jorquera, Juan I. ;
Kempf, Christoph ;
Kreil, Thomas R. ;
Pifat, Dominique ;
Osheroff, Wendy ;
Poelsler, Gerhard .
TRANSFUSION, 2009, 49 (09) :1931-1943
[5]
Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution [J].
Dichtelmüller, H ;
Rudnick, D ;
Kloft, M .
BIOLOGICALS, 2002, 30 (02) :135-142
[6]
*EUR AG EV MED PRO, 1996, CPMPBWP26895
[7]
*EUR AG EV MED PRO, 2001, CPMPBWP26995
[8]
*EUR MED AG, 2009, CPMPBWP26995
[9]
STUDIES ON NEW PROCESS PROCEDURES IN PLASMA FRACTIONATION ON AN INDUSTRIAL-SCALE .3. REMOVAL OF PRECIPITATES BY FILTRATION THROUGH A HORIZONTAL LEAF FILTER WITH CENTRIFUGAL CLEANING (FUNDA FILTER) AS AN ALTERNATIVE TO TUBULAR-BOWL CENTRIFUGES [J].
FRIEDLI, H ;
MAUERHOFER, M ;
FAES, A ;
KISTLER, P .
VOX SANGUINIS, 1976, 31 (04) :289-295
[10]
CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION .36. INACTIVATION OF THE VIRUS OF HOMOLOGOUS SERUM HEPATITIS IN SOLUTIONS OF NORMAL HUMAN SERUM ALBUMIN BY MEANS OF HEAT [J].
GELLIS, SS ;
NEEFE, JR ;
STOKES, J ;
STRONG, LE ;
JANEWAY, CA ;
SCATCHARD, G .
JOURNAL OF CLINICAL INVESTIGATION, 1948, 27 (02) :239-244